Accelerating Oncology Launch: How CMK Select Reduced Delays by 60%

CHALLENGE

A leading pharmaceutical company was developing an oncology compound that received FDA Breakthrough Therapy designation, granting expedited approval. With this designation, the company faced a critical challenge: ensuring adequate drug supply at launch to meet urgent patient needs and capitalize on early revenue opportunities. However, the existing timeline projected a two-month delay in product availability post-launch, risking negative public perception and lost revenue.

SOLUTION

CMK Select conducted a comprehensive timeline review, identifying risks and opportunities. Through stakeholder interviews, we aligned brand objectives and ideal timelines. Our analysis revealed that the current schedule would result in a highly unfavorable two-month delay. To address this, CMK Select convened key decision-makers from manufacturing and distribution, streamlining processes and prioritizing tasks that could be completed ahead of time. This proactive approach optimized operational readiness and accelerated execution.

IMPACT & VALUE REALIZED

CMK Select’s strategic intervention led to a dramatic improvement in launch readiness and operational efficiency. By realigning priorities, streamlining decision-making, and accelerating key manufacturing and distribution activities, the team achieved a 60% reduction in launch delays, ensuring product availability less than two weeks post-launch instead of the two-month lag initially projected. This acceleration delivered five additional weeks of revenue, strengthened the company’s market position, and eliminated the risk of negative publicity tied to product unavailability. The success of this initiative prompted the client to institutionalize CMK’s streamlined process as a best practice for future product launches.